公开(公告)号：EP4361152A1

公开(公告)日：2024-05-01

申请号：EP22827576.4

申请日：2022-06-21

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. ,  Shouyao Holdings (Beijing) Co., Ltd. ,  Lianyungang Runzhong Pharmaceutical Co., Ltd.

发明人： TU, Lifan ,  ZHANG, Xiquan ,  WANG, Xunqiang ,  YU, Ding ,  HUANG, Jianqiang

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61P37/06

CPC分类号： C07D487/04 ,  A61K31/519 ,  A61P37/06

摘要： The present invention relates to the use of a pyrrolopyrimidine compound and a pharmaceutical composition thereof for treating chronic graft versus host disease, and particularly relates to the use of a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof for treating chronic graft versus host disease.

公开(公告)号：EP3744325A1

公开(公告)日：2020-12-02

申请号：EP19740851.1

申请日：2019-01-16

申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

发明人： HUA, Yingqi ,  WANG, Gangyang ,  CAI, Zhengdong ,  WANG, Zhuoying ,  ZHANG, Tao ,  WANG, Hongsheng ,  SUN, Mengxiong ,  WANG, Xunqiang ,  ZHAN, Xiaole ,  YANG, Zhaoqiang ,  TU, Lifan ,  LI, Pu

IPC分类号： A61K31/4709 ,  A61P35/00

摘要： The present disclosure relates to a new use of anlotinib, belongs to the technical field of drugs, and relates in particular to anlotinib inhibiting osteosarcoma and chondrosarcoma growth and metastasis. It has been discovered for the first time that anlotinib may inhibit osteosarcoma and chondrosarcoma growth and metastasis. Anlotinib can significantly inhibit the growth of the osteosarcoma cell lines 143B, U2OS, MG63 and SJSA, induce cycle arrest in said cell lines, and can also inhibit osteosarcoma cell line migration and invasion. It has also been discovered for the first time that anlotinib can enhance the killing effect of the chemotherapeutic drug cisplatin on osteosarcoma cells.

公开(公告)号：EP3957631A1

公开(公告)日：2022-02-23

申请号：EP20790646.2

申请日：2020-04-20

申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

发明人： ZHAN, Xiaole ,  TU, Lifan ,  YANG, Chaoqiang ,  ZHANG, Xiquan ,  WANG, Xunqiang ,  XU, Jie ,  XU,Ping ,  WANG,Chengqian

IPC分类号： C07D401/12 ,  A61K31/4709 ,  A61K45/06 ,  A61P35/00

摘要： The present invention belongs to the field of medicine, and provides a quinoline compound or a pharmaceutically acceptable salt thereof for treating Ewing's sarcoma, and particularly relates to use of compound I or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating Ewing's sarcoma and use of compound I or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent in the preparation of a combination medicament for treating Ewing's sarcoma. The chemical name of compound I is 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropanamine.